Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal treatment of perianal Crohn's fistulas: seton vs anti-TNF vs advancement plasty/LIFT
NL-OMON45001Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab, adalimumab and mercaptopurine in Crohn's disease and anal fistula (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Number of patients needing fistula-related re-interventions. Started Nov 2013; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on NL-OMON45001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45001.